Argenica Therapeutics Ltd (AGN.AX) Stock Competitors & Peer Comparison
See (AGN.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AGN.AX | A$0.12 | +9.09% | 15.4M | -1.58 | -A$0.08 | N/A |
| CSL.AX | A$121.81 | +3.45% | 58.3B | 13.10 | A$9.30 | +3.62% |
| TLX.AX | A$16.88 | -1.75% | 5.7B | -609.17 | -A$0.03 | N/A |
| MSB.AX | A$2.06 | +0.49% | 2.7B | -13.85 | -A$0.15 | N/A |
| NEU.AX | A$16.74 | -1.53% | 2.1B | 71.26 | A$0.23 | N/A |
| PYC.AX | A$1.54 | -4.64% | 895M | -33.66 | -A$0.05 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | 6.14 | A$0.10 | N/A |
| CUV.AX | A$10.25 | -0.10% | 516.7M | 15.91 | A$0.64 | +0.49% |
| RAC.AX | A$2.29 | +0.44% | 449M | -110.63 | -A$0.02 | N/A |
| SPL.AX | A$0.74 | +3.52% | 309.4M | 116.67 | A$0.01 | N/A |
Stock Comparison
AGN.AX vs CSL.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, CSL.AX has a market cap of 58.3B. Regarding current trading prices, AGN.AX is priced at A$0.12, while CSL.AX trades at A$121.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas CSL.AX's P/E ratio is 13.10. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, AGN.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check CSL.AX's competition here
AGN.AX vs TLX.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, TLX.AX has a market cap of 5.7B. Regarding current trading prices, AGN.AX is priced at A$0.12, while TLX.AX trades at A$16.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas TLX.AX's P/E ratio is -609.17. In terms of profitability, AGN.AX's ROE is -1.84%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, AGN.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check TLX.AX's competition here
AGN.AX vs MSB.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, MSB.AX has a market cap of 2.7B. Regarding current trading prices, AGN.AX is priced at A$0.12, while MSB.AX trades at A$2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas MSB.AX's P/E ratio is -13.85. In terms of profitability, AGN.AX's ROE is -1.84%, compared to MSB.AX's ROE of -0.16%. Regarding short-term risk, AGN.AX is more volatile compared to MSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check MSB.AX's competition here
AGN.AX vs NEU.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, NEU.AX has a market cap of 2.1B. Regarding current trading prices, AGN.AX is priced at A$0.12, while NEU.AX trades at A$16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas NEU.AX's P/E ratio is 71.26. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, AGN.AX is more volatile compared to NEU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check NEU.AX's competition here
AGN.AX vs PYC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, PYC.AX has a market cap of 895M. Regarding current trading prices, AGN.AX is priced at A$0.12, while PYC.AX trades at A$1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas PYC.AX's P/E ratio is -33.66. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, AGN.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PYC.AX's competition here
AGN.AX vs OPT.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, AGN.AX is priced at A$0.12, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas OPT.AX's P/E ratio is 6.14. In terms of profitability, AGN.AX's ROE is -1.84%, compared to OPT.AX's ROE of -3.12%. Regarding short-term risk, AGN.AX is more volatile compared to OPT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check OPT.AX's competition here
AGN.AX vs CUV.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, CUV.AX has a market cap of 516.7M. Regarding current trading prices, AGN.AX is priced at A$0.12, while CUV.AX trades at A$10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas CUV.AX's P/E ratio is 15.91. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, AGN.AX is more volatile compared to CUV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check CUV.AX's competition here
AGN.AX vs RAC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, RAC.AX has a market cap of 449M. Regarding current trading prices, AGN.AX is priced at A$0.12, while RAC.AX trades at A$2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas RAC.AX's P/E ratio is -110.63. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, AGN.AX is more volatile compared to RAC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check RAC.AX's competition here
AGN.AX vs SPL.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, SPL.AX has a market cap of 309.4M. Regarding current trading prices, AGN.AX is priced at A$0.12, while SPL.AX trades at A$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas SPL.AX's P/E ratio is 116.67. In terms of profitability, AGN.AX's ROE is -1.84%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, AGN.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check SPL.AX's competition here
AGN.AX vs OCC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, OCC.AX has a market cap of 167.7M. Regarding current trading prices, AGN.AX is priced at A$0.12, while OCC.AX trades at A$0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas OCC.AX's P/E ratio is -27.96. In terms of profitability, AGN.AX's ROE is -1.84%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, AGN.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check OCC.AX's competition here
AGN.AX vs ATH.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ATH.AX has a market cap of 145.7M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ATH.AX trades at A$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ATH.AX's P/E ratio is -394.12. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, AGN.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ATH.AX's competition here
AGN.AX vs DXB.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, DXB.AX has a market cap of 144.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while DXB.AX trades at A$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas DXB.AX's P/E ratio is -4.81. In terms of profitability, AGN.AX's ROE is -1.84%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, AGN.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check DXB.AX's competition here
AGN.AX vs ACW.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ACW.AX has a market cap of 135.7M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ACW.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ACW.AX's P/E ratio is -6.34. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, AGN.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ACW.AX's competition here
AGN.AX vs PAA.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, AGN.AX is priced at A$0.12, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, AGN.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PAA.AX's competition here
AGN.AX vs RCE.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, RCE.AX has a market cap of 108.4M. Regarding current trading prices, AGN.AX is priced at A$0.12, while RCE.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas RCE.AX's P/E ratio is -4.12. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, AGN.AX is more volatile compared to RCE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check RCE.AX's competition here
AGN.AX vs ILA.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ILA.AX has a market cap of 93.8M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ILA.AX trades at A$0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ILA.AX's P/E ratio is -12.02. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, AGN.AX is more volatile compared to ILA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check ILA.AX's competition here
AGN.AX vs ALA.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ALA.AX has a market cap of 83.4M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ALA.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ALA.AX's P/E ratio is -9.70. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, AGN.AX is more volatile compared to ALA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check ALA.AX's competition here
AGN.AX vs IMM.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, IMM.AX has a market cap of 81.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while IMM.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas IMM.AX's P/E ratio is -0.96. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, AGN.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check IMM.AX's competition here
AGN.AX vs ATX.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ATX.AX has a market cap of 77M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ATX.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ATX.AX's P/E ratio is -8.67. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ATX.AX's ROE of -0.19%. Regarding short-term risk, AGN.AX is more volatile compared to ATX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check ATX.AX's competition here
AGN.AX vs PAR.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, PAR.AX has a market cap of 75.8M. Regarding current trading prices, AGN.AX is priced at A$0.12, while PAR.AX trades at A$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas PAR.AX's P/E ratio is -2.40. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, AGN.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PAR.AX's competition here
AGN.AX vs PTX.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, PTX.AX has a market cap of 71.5M. Regarding current trading prices, AGN.AX is priced at A$0.12, while PTX.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas PTX.AX's P/E ratio is -7.48. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, AGN.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PTX.AX's competition here
AGN.AX vs AVE.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, AVE.AX has a market cap of 68.2M. Regarding current trading prices, AGN.AX is priced at A$0.12, while AVE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas AVE.AX's P/E ratio is -16.20. In terms of profitability, AGN.AX's ROE is -1.84%, compared to AVE.AX's ROE of -2.58%. Regarding short-term risk, AGN.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check AVE.AX's competition here
AGN.AX vs BIO.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, BIO.AX has a market cap of 65M. Regarding current trading prices, AGN.AX is priced at A$0.12, while BIO.AX trades at A$0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas BIO.AX's P/E ratio is 67.86. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, AGN.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BIO.AX's competition here
AGN.AX vs IMU.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, IMU.AX has a market cap of 56.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while IMU.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas IMU.AX's P/E ratio is -0.99. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, AGN.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check IMU.AX's competition here
AGN.AX vs ENP.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ENP.AX has a market cap of 52.2M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ENP.AX's ROE of -0.68%. Regarding short-term risk, AGN.AX is less volatile compared to ENP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ENP.AX's competition here
AGN.AX vs RAD.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, RAD.AX has a market cap of 47.3M. Regarding current trading prices, AGN.AX is priced at A$0.12, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas RAD.AX's P/E ratio is -0.97. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, AGN.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check RAD.AX's competition here
AGN.AX vs BOT.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, BOT.AX has a market cap of 41.8M. Regarding current trading prices, AGN.AX is priced at A$0.12, while BOT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas BOT.AX's P/E ratio is -0.62. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, AGN.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BOT.AX's competition here
AGN.AX vs NOX.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, NOX.AX has a market cap of 28.3M. Regarding current trading prices, AGN.AX is priced at A$0.12, while NOX.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas NOX.AX's P/E ratio is -4.90. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, AGN.AX is more volatile compared to NOX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check NOX.AX's competition here
AGN.AX vs MEM.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, MEM.AX has a market cap of 24.7M. Regarding current trading prices, AGN.AX is priced at A$0.12, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas MEM.AX's P/E ratio is -3.81. In terms of profitability, AGN.AX's ROE is -1.84%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, AGN.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check MEM.AX's competition here
AGN.AX vs LCT.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, AGN.AX is priced at A$0.12, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, AGN.AX is more volatile compared to LCT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check LCT.AX's competition here
AGN.AX vs NC6.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, NC6.AX has a market cap of 23.5M. Regarding current trading prices, AGN.AX is priced at A$0.12, while NC6.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas NC6.AX's P/E ratio is -8.68. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, AGN.AX is less volatile compared to NC6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check NC6.AX's competition here
AGN.AX vs 1AI.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, 1AI.AX has a market cap of 23.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while 1AI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, AGN.AX is more volatile compared to 1AI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check 1AI.AX's competition here
AGN.AX vs EZZ.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, EZZ.AX has a market cap of 20.9M. Regarding current trading prices, AGN.AX is priced at A$0.12, while EZZ.AX trades at A$0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas EZZ.AX's P/E ratio is 7.27. In terms of profitability, AGN.AX's ROE is -1.84%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, AGN.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check EZZ.AX's competition here
AGN.AX vs NSB.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, NSB.AX has a market cap of 20.3M. Regarding current trading prices, AGN.AX is priced at A$0.12, while NSB.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas NSB.AX's P/E ratio is -4.21. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, AGN.AX is more volatile compared to NSB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check NSB.AX's competition here
AGN.AX vs KZA.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, AGN.AX is priced at A$0.12, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, AGN.AX's ROE is -1.84%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, AGN.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check KZA.AX's competition here
AGN.AX vs BTC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, BTC.AX has a market cap of 18M. Regarding current trading prices, AGN.AX is priced at A$0.12, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas BTC.AX's P/E ratio is -21.89. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, AGN.AX is more volatile compared to BTC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check BTC.AX's competition here
AGN.AX vs MDC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas MDC.AX's P/E ratio is -7.07. In terms of profitability, AGN.AX's ROE is -1.84%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, AGN.AX is more volatile compared to MDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check MDC.AX's competition here
AGN.AX vs PAB.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, PAB.AX has a market cap of 13.3M. Regarding current trading prices, AGN.AX is priced at A$0.12, while PAB.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas PAB.AX's P/E ratio is -3.29. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PAB.AX's ROE of -4.06%. Regarding short-term risk, AGN.AX is less volatile compared to PAB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PAB.AX's competition here
AGN.AX vs BNO.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, AGN.AX is priced at A$0.12, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BNO.AX's ROE of +0.47%. Regarding short-term risk, AGN.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BNO.AX's competition here
AGN.AX vs CMB.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, CMB.AX has a market cap of 10M. Regarding current trading prices, AGN.AX is priced at A$0.12, while CMB.AX trades at A$0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas CMB.AX's P/E ratio is -6.21. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CMB.AX's ROE of -1.62%. Regarding short-term risk, AGN.AX is more volatile compared to CMB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check CMB.AX's competition here
AGN.AX vs IMC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, IMC.AX has a market cap of 9.3M. Regarding current trading prices, AGN.AX is priced at A$0.12, while IMC.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas IMC.AX's P/E ratio is -1.93. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, AGN.AX is more volatile compared to IMC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check IMC.AX's competition here
AGN.AX vs TRP.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, TRP.AX has a market cap of 7.3M. Regarding current trading prices, AGN.AX is priced at A$0.12, while TRP.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas TRP.AX's P/E ratio is -1.89. In terms of profitability, AGN.AX's ROE is -1.84%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, AGN.AX is less volatile compared to TRP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check TRP.AX's competition here
AGN.AX vs IXC.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, IXC.AX has a market cap of 7.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while IXC.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas IXC.AX's P/E ratio is -8.57. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, AGN.AX is more volatile compared to IXC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check IXC.AX's competition here
AGN.AX vs VBS.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, VBS.AX has a market cap of 6.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while VBS.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas VBS.AX's P/E ratio is -4.35. In terms of profitability, AGN.AX's ROE is -1.84%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, AGN.AX is more volatile compared to VBS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check VBS.AX's competition here
AGN.AX vs ZLD.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ZLD.AX's P/E ratio is -1.58. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ZLD.AX's ROE of +0.81%. Regarding short-term risk, AGN.AX is more volatile compared to ZLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check ZLD.AX's competition here
AGN.AX vs ACR.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ACR.AX has a market cap of 4.8M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ACR.AX's P/E ratio is -1.09. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, AGN.AX is more volatile compared to ACR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check ACR.AX's competition here
AGN.AX vs BGT.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, BGT.AX has a market cap of 4.6M. Regarding current trading prices, AGN.AX is priced at A$0.12, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas BGT.AX's P/E ratio is -2.39. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, AGN.AX is more volatile compared to BGT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check BGT.AX's competition here
AGN.AX vs BIT.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, BIT.AX has a market cap of 4.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas BIT.AX's P/E ratio is -7.58. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, AGN.AX is less volatile compared to BIT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BIT.AX's competition here
AGN.AX vs RGS.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, AGN.AX is priced at A$0.12, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, AGN.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check RGS.AX's competition here
AGN.AX vs CYP.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, CYP.AX has a market cap of 3.2M. Regarding current trading prices, AGN.AX is priced at A$0.12, while CYP.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas CYP.AX's P/E ratio is -0.42. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, AGN.AX is more volatile compared to CYP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check CYP.AX's competition here
AGN.AX vs 1AD.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, 1AD.AX has a market cap of 2.4M. Regarding current trading prices, AGN.AX is priced at A$0.12, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas 1AD.AX's P/E ratio is -0.26. In terms of profitability, AGN.AX's ROE is -1.84%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, AGN.AX is less volatile compared to 1AD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check 1AD.AX's competition here
AGN.AX vs CHM.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, CHM.AX has a market cap of 2.4M. Regarding current trading prices, AGN.AX is priced at A$0.12, while CHM.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas CHM.AX's P/E ratio is -0.17. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, AGN.AX is more volatile compared to CHM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check CHM.AX's competition here
AGN.AX vs ANR.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, ANR.AX has a market cap of 2.1M. Regarding current trading prices, AGN.AX is priced at A$0.12, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas ANR.AX's P/E ratio is -1.25. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, AGN.AX is more volatile compared to ANR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check ANR.AX's competition here
AGN.AX vs EX1.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, AGN.AX is priced at A$0.12, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, AGN.AX's ROE is -1.84%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, AGN.AX is more volatile compared to EX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check EX1.AX's competition here
AGN.AX vs HXL.AX Comparison July 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 15.4M. In comparison, HXL.AX has a market cap of 542.9K. Regarding current trading prices, AGN.AX is priced at A$0.12, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.58, whereas HXL.AX's P/E ratio is -0.58. In terms of profitability, AGN.AX's ROE is -1.84%, compared to HXL.AX's ROE of -0.14%. Regarding short-term risk, AGN.AX is more volatile compared to HXL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AGN.AX.Check HXL.AX's competition here